These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24387233)

  • 1. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
    Sonpavde G; Willey CD; Sudarshan S
    Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
    Saylor PJ; Escudier B; Michaelson MD
    Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting angiogenesis in renal cell carcinoma.
    Posadas EM; Limvorasak S; Sharma S; Figlin RA
    Expert Opin Pharmacother; 2013 Nov; 14(16):2221-36. PubMed ID: 23984807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
    Massari F; Ciccarese C; Santoni M; Lopez-Beltran A; Scarpelli M; Montironi R; Cheng L
    Expert Rev Anticancer Ther; 2015; 15(12):1367-9. PubMed ID: 26568023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tyrosine kinase inhibitors for renal cell carcinoma.
    Dorff TB; Pal SK; Quinn DI
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
    Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
    Sawhney R; Kabbinavar F
    Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
    Choueiri TK; Bukowski RM; Rini BI
    Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
    Adachi Y; Kamiyama H; Ichikawa K; Fukushima S; Ozawa Y; Yamaguchi S; Goda S; Kimura T; Kodama K; Matsuki M; Miyano SW; Yokoi A; Kato Y; Funahashi Y
    Cancer Res; 2022 Jan; 82(2):292-306. PubMed ID: 34753772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.